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Abstract: 
Introduction: Conclusive data on the accuracy and clinical applicability of 
non-invasive screening tests for oesophageal varices (OV) in patients with 
compensated cirrhosis remain lacking. We conducted this study to identify 
currently available tests, estimate their diagnostic performance, and then 
exemplify how these could be utilized in clinical practice.  
 
Materials and methods: A systematic literature search was performed to 
identify all primary studies which reported accuracy using 
oesophagogastroduodenoscopy (OGD) as the gold standard. Sources 
searched included OVID MEDLINE; OVID EMBASE; and The Cochrane 
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Library databases for studies published from database inception to March 
1st 2017.  
 
Results: 21 studies with a total of 2,471 patients were identified. The 
following tests were evaluated in ≥3 studies: platelet count/spleen 
diameter ratio (PSR) (n=9), liver stiffness measurement (LSM) (n=5), 
platelet count (n=5), spleen stiffness measurement (n=3), aspartate 
aminotransferase to platelet ratio index (n=3). PSR had the highest 
summary area under the curve for detection of any size OV of 0.85 (95% 
confidence interval 0.78-0.92). At a cut-off of 909 (n=4 studies) and 
prevalence rates of 10%, 20%, 30%, 40%, 50% for OV; PSR screening 
correctly avoided the need for OGD in 70%, 62%, 55%, 47%, and 39% of 
patients, respectively.  
 
Conclusions: PSR appears to be the most accurate and validated non-
invasive screening test for OV in patients with compensated cirrhosis. At a 
cut-off of 909, PSR could be clinically useful to avoid OGDs in a significant 
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Abstract 
Introduction: Conclusive data on the accuracy and clinical applicability of non-invasive 
screening tests for oesophageal varices (OV) in patients with compensated cirrhosis remain 
lacking. We conducted this study to identify currently available tests, estimate their 
diagnostic performance, and then exemplify how these could be utilized in clinical practice.  
Materials and methods: A systematic literature search was performed to identify all primary 
studies which reported accuracy using oesophagogastroduodenoscopy (OGD) as the gold 
standard. Sources searched included OVID MEDLINE; OVID EMBASE; and The Cochrane 
Library databases.   
Results: 21 studies with a total of 2,471 patients were identified. Several tests were 
evaluated in ≥3 studies. Platelet count/spleen diameter ratio (PSR) had the highest summary 
area under the curve for detection of any size OV of 0.85 (95% confidence interval 0.78-
0.92). At a cut-off of 909 (n=4 studies) and prevalence rates of 10%, 20%, 30%, 40%, 50% 
for OV; PSR screening correctly avoided the need for OGD in 70%, 62%, 55%, 47%, and 
39% of patients, respectively. 
Conclusions: PSR appears to be the most accurate and validated non-invasive screening 
test for OV in patients with compensated cirrhosis. At a cut-off of 909, PSR could be 
clinically useful to avoid OGDs in a significant proportion of patients.    
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• The majority of patients with compensated cirrhosis undergoing invasive screening with 
oesophagogastroduodenoscopy (OGD) do not have oesophageal varices (OV). 
• Several non-invasive tests have been evaluated in this setting with variable results and 
cut-off values. The value of these tests in clinical practice remains unclear. 
• Currently available non-invasive tests for OV specific to patients with compensated 
cirrhosis are identified and compared. 
• Platelet count/spleen diameter ratio (PSR) appears to be the most accurate and 
validated test for OV in this cohort. At a cut-off of 909, PSR could be clinically utilized to 
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Current guidelines recommend screening all patients diagnosed with liver cirrhosis for 
oesophageal varices (OV) using oesophagogastroduodenoscopy (OGD) 1. Present 
estimates suggest that only 30-40% of patients with compensated cirrhosis have OV at the 
index OGD 2. Moreover, the prevalence of medium/large OV in those patients is low at 
approximately 10% 3. Therefore, a large proportion of compensated cirrhosis patients 
currently undergo serial negative OGDs at a significant cost and additional discomfort 4 with 
potentially marginal clinical benefit5. In fact, empirical therapy with non-selective beta 
blockers was more cost-effective than OGD screening when both strategies were compared 
to no screening5. Thus, the stratification of patients with OV and judicious selction of patients 
for therapy is an important and common clincial problem. 
A large number of studies have evaluated the accuracy of non-invasive serum and imaging 
biomarkers in predicting the presence of OV. However, both individual studies and meta-
analyses have inherent limitations as they are performed on heterogeneous populations with 
both compensated and decompensated cirrhosis; hence they are subject to high risk of 
spectrum bias and are challenging to translate into clinical practice 6-8. Compensated 
cirrhosis represents a significantly different clinical entity with lower prevalence of OV as well 
as lower risk of variceal bleeding and death compared to decompensated cirrhosis9.  
The availability of simple, non-invasive tests of liver fibrosis, and advances in radiological 
imaging will inevitably result in the earlier diagnosis of cirrhosis 10. This will enrich the 
number of patients with compensated cirrhosis and having data specific to this population 
will be imperative in guiding bespoke management strategies. The aims of this study were 
to: 1) Identify, using a systematic review, non-invasive diagnostic tests that detect OV in 
compensated cirrhosis; 2) Compare overall diagnostic performance, using meta-analysis, of 
different diagnostic tests in compensated cirrhosis; and 3) Create a clinical applicability 
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model to highlight the number of OGDs that could be saved using non-invasive tests at a 
specified threshold and varying prevalence of OV. 
Materials and Methods 
This study was conducted according to guidance provided by the Cochrane Collaboration 
handbook for systematic reviews 11, and following a pre-specified protocol.  
Search Strategy 
We searched OVID MEDLINE; OVID EMBASE; and The Cochrane Library databases for 
studies published from database inception to March 1st 2017 for relevant articles evaluating 
all diagnostic tests for the prediction of OV in patients with compensated cirrhosis. No 
restrictions were applied to the search algorithm (Supplementary Table 1).  
Study selection and outcome measures 
Studies were included if: 
1) They were performed on adult patients aged 18 years or older.  
2) Subjects had proven liver cirrhosis of any aetiology, defined by typical clinical and  
radiological with or without histological criteria 12. 
3) Patients had compensated cirrhosis as defined by Child Pugh A grade, or absence of 
ascites, encephalopathy, and previous variceal haemorrhage.  
4) OGD was used as the reference standard.  
5) Sufficient data was provided to allow generation of a 2x2 diagnostic table.  
The primary outcome measure was the diagnostic performance of index tests for the 
detection of any size OV. This was chosen because identification of any OV in patients with 
compensated cirrhosis results in a change in clinical management, either by reduced interval 
of surveillance OGD or initiation of primary prophylaxis measures to prevent an index 
variceal bleed.  
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Study quality was assessed independently by two investigators (SSS and DH) using the 
updated version of the quality assessment of diagnostic accuracy studies (QUADAS-2) 
tool13.  
Statistical analysis 
Meta-analyses were performed using the DerSimonian-Laird random effects model 14 to 
calculate (with 95% confidence intervals [CIs]): pooled sensitivity, specificity, positive 
likelihood ratio (LR+), negative likelihood ratio (LR-), DOR, and summary AUC. Summary 
receiver operating characteristic (SROC) curves were used to compare the overall accuracy 
of different tests 15. 
We aimed to estimate the proportion of OGDs saved by implementing a pre-screening 
strategy with a non-invasive marker compared to the current practice of universal screening. 
This clinical applicability was evaluat d using the likelihood ratios to calculate post-test 
probability based on Bayes's theorem 16. This concept is depicted visually with a Fagan's 
Bayesian nomogram 16. Estimates of the pre-test probability of OV were derived from the 
pooled prevalence across all studies as well as other prevalence rates reported in the 
literature. The clinical applicability was measured only for tests that are validated in more 
than one study using the same threshold as identified by our systematic review. Analysis 
was performed using Meta-DiSc (version 1.4, Ramón y Cajal Hospital, Madrid, Spain) and 
Stata (version 12.1, College Station, Texas, USA) software packages.  
Heterogeneity, subgroup analyses, and publication bias 
Heterogeneity was examined both by visual inspection of the forest plots, and by statistical 
assessment using the chi square and inconsistency (I2) test. The I2 describes the percentage 
of total variation across studies that is due to heterogeneity rather than chance. Values of I2 
of 25%, 50% and 75% may be considered to represent low, moderate and high 
inconsistency 17. Exploratory subgroup analyses were conducted to investigate sources of 
heterogeneity.  Evidence of publication bias or small study effects was assessed using both 
Page 7 of 38
htpp://mc.manuscriptcentral.com/UEGH


































































visual inspection of the funnel plot and Deek’s asymmetry test 18 whenever there were 
approximately 10 or more studies included in the meta-analysis 19. A p-value of <0.10 was 
suggestive of significant asymmetry and therefore the possible presence of publication bias.  
Results 
The search strategy identified 5,527 citations which were all screened by reading the title 
and abstract. We identified 185 potentially eligible articles which were all read in full. 21 
studies with a total 2,471 patients with compensated cirrhosis were included in the 
systematic review 20-40. Fifteen studies (1,695 patients) 20-33, 39 evaluated similar markers and 
were also included in the meta-analysis (Figure 1). Details are summarized in Table 1, and 
2, respectively. Results of the QUADAS-2 quality assessment are shown in supplementary 
Table 2.  
Diagnostic tests identified 
Platelet count/spleen diameter ratio (PSR) 
9 studies (n=823 patients) 20-28 evaluated PSR for the diagnosis of any size OV in patients 
with compensated cirrhosis. The pooled sensitivity and specificity were 0.87 (95%CI 0.83-
0.90) and 0.71 (95%CI 0.67-0.75), respectively (Figure 2 and Table 3). The summary AUC 
was 0.85 (95%CI 0.78-0.92) (supplementary Figure 1). Only one study evaluated the 
accuracy of PSR for the detection of medium/large OV 28. There was evidence of significant 
heterogeneity between studies, and subgroup analyses (supplementary Table 3) identified 
study location as the only significant source of heterogeneity (DOR: western=8.8 (95%CI 
3.8-20.0) vs. non-western=255.9 (95%CI 33.4-1962.4); p=0.0130). No evidence of significant 
publication bias was detected (p=0.88). 
Liver stiffness measurement (LSM) 
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5 studies (n=553 patients) evaluated the accuracy of LSM by transient elastography 
(Fibroscan®, Echosens, Paris, France) for the diagnosis of any size OV 26, 28-31. Variable cut-
offs were used (16.4 kPa, 17 kPa, 12 kPa, 13.9 kPa, and 21.5 kPa) (Table 1). The pooled 
sensitivity and specificity were 0.83 (95%CI 0.77-0.87) and 0.60 (95%CI 0.54-0.65), 
respectively (Figure 3). The summary AUC was 0.78 (95%CI 0.73-0.83) (supplementary 
Figure 2). 5 studies (n=664 patients) reported the accuracy of LSM for the diagnosis of 
medium/large OV 28-32 (Table 3).  
Platelet count 
3 studies (n=216 patients) evaluated the accuracy of platelets count for the diagnosis of any 
size OV 25, 29, 31. Cut-offs analysed were 117, 140, and 221 *103/microL (Table 1). The pooled 
sensitivity, specificity, and summary AUC were 0.65 (95%CI 0.54-0.75), 0.72 (95%CI 0.64-
0.79), and 0.76 (95%CI 0.71-0.81), respectively. 4 studies (n=481 patients) evaluated the 
accuracy of platelets count for the diagnosis of medium/large OV 29, 31-33 (Table 3).     
Spleen stiffness measurement (SSM) 
3 studies assessed the accuracy of SSM for the detection of any OV (n=422 patients) 26, 28, 
39. The pooled sensitivity, specificity, and summary AUC were 0.88 (95%CI 0.82-0.92), 0.64 
(95%CI 0.57-0.70), and 0.66 (95%CI 0.59-0.73), respectively (Table 3). In the study by 
Takuma et al 39, the acoustic radiation force impulse (ARFI) technique was used for SSM, 
while the other two studies used the Fibroscan 26, 28. Two of the three studies above also 
reported data on accuracy for medium/large OV 28, 39 (Table 1).   
Aspartate aminotransferase to platelet ratio index (APRI) 
The APRI test was evaluated in 3 studies with regards to the detection of any OV as well as 
medium/large OV (n=292 patients) 28, 29, 31. The pooled sensitivity, specificity, and summary 
AUC for the diagnosis of any OV were 0.69 (95%CI 0.60-0.77), 0.62 (95%CI 0.55-0.70), and 
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0.77 (95%CI 0.71-0.83), respectively (threshold effect, p<0.001). Data for medium/large OV 
are shown in Table 3 (threshold effect, p<0.001).   
Other tests 
Several other non-invasive tests have been evaluated with variable results (Table1).   
Clinical applicability model 
PSR was the only non-invasive marker that had multiple validation studies at a consistent 
threshold (4 studies used the 909 cut-off) 20, 21, 23, 27 (supplementary Table 3), hence included 
in the model. At the 909 cut-off, the pooled sensitivity, specificity, LR+, and LR- for the 
diagnosis of any size OV were 0.87 (95%CI 0.81-0.92), 0.78 (95%CI 0.73-0.83), 4.0 (95%CI 
1.9-7.8), and 0.16 (0.02-0.71), respectively (supplementary Table 3). These values were 
applied to 5 different hypothetical cohorts with prevalence rates for any size OV at 10%; 
20%; 30%; 40%; and 50%. The proportions of correctly saved endoscopies (true negative) 
were 70%, 62%, 55%, 47%, and 39%, respectively; while the proportions of incorrectly 
saved endoscopies (false negative) in those 5 cohorts were 1%. 2.5%, 4%, 5%, and 6%, 
respectively (Figure 4). Results of all Fagan’s plots are shown in supplementary Figure 3.    
Discussion 
Principal findings 
This is the first comprehensive systematic review (including 2,471 patients) and meta-
analysis (including 1,695 patients) of all non-invasive diagnostic tests for the detection of OV 
in patients with compensated cirrhosis using the same methodology. The vast majority of 
studies were published within the last decade which highlights the recent and ongoing 
search for alternative pathways to improve the effectiveness of screening in this low risk 
group with cirrhosis. Focusing on tests included in the meta-analysis, PSR was the most 
frequently evaluated with 9 studies in total 20-28, followed by LSM (5 studies) 26, 28-31, platelet 
count (5 studies) 25, 29, 31-33, SSM (3 studies) 26, 28, 39, and APRI (3 studies) 28, 29, 31. For the 
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diagnosis of any size OV across all cut-offs, PSR had the highest summary AUC compared 
to other tests (0.85; 95%CI 0.78-0.92), while the accuracy of LSM was higher than platelet 
count and APRI for the detection of medium/large OV (summary AUC 0.85; 95%CI 0.80-
0.90) (Table 3).  
Pooled data on the performance of the aforementioned tests represent a global summary of 
test accuracy based on current literature. However, these values have limited inference and 
cannot be adopted into clinical practice due to the variation in cut-offs used for each test. We 
tested PSR at the single 909 threshold, validated by multiple studies, within a clinical 
applicability model.  We demonstrated that a significant proportion of OGDs could be saved 
ranging from 39% to 70% dependent on the prevalence of OV with a respective range of 
50% to 10%. This provides encouraging evidence that existing non-invasive markers could 
be adopted into clinical practice. Our data suggest that the benefits of PSR become less 
evident in the context of  high prevalence of OV (50% or higher) which is more likely to occur 
in decompensated cirrhosis3. 
Study strengths and limitations 
This systematic review and meta-analysis had several strengths. We only evaluated patients 
with compensated cirrhosis as defined by the Baveno IV criteria 41. It is now recognized that 
the development of diagnostic tests and prognostic models should be specific to each 
clinical status (compensated vs. decompensated), because treatment aims and outcomes 
are different in those two groups of patients 41. Some studies reported data on patients with 
compensated cirrhosis as a subgroup within the main article. In order not to miss such 
studies, our search strategy was designed to be inclusive of all patients with cirrhosis 
regardless of their compensation status; therefore we reviewed a large number (n=185) of 
manuscripts in full to identify the eligible 21 studies which were included in this review. 
Moreover, we evaluated all currently available tests in the literature and obtained pooled 
data for some of the tests using the same methodology, hence, this enables direct 
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comparisons between the tests’ global accuracy to be made rather than relying on indirect 
comparisons from individual meta-analyses which use different methodologies and 
inclusion/exclusion criteria. Finally, we presented a tangible outcome measure using a 
clinical applicability model to estimate the potential reduction in unnecessary screening 
endoscopies by adopting a non-invasive marker into the OV testing algorithm.  
There are also several limitations that need to be considered when interpreting the results. 
As with most diagnostic accuracy meta-analyses 11, we observed high heterogeneity across 
studies evaluating PSR, LSM, and SSM.  In case of PSR, this could be explained based on 
the location where the study was performed, but in case of other markers, subgroup 
analyses were not performed due to the small number of studies available. There may be 
several possible explanations for heterogeneity including study-, patient-, or test-related 
factors (supplementary Table 2). Variation in diagnostic thresholds used for the same test 
could be an important source of heterogeneity. We accounted for this in our analysis and 
found no evidence of a significant threshold effect in case of PSR, LSM, and SSM studies (p 
value >0.05 for all analyses), but not in case of platelet count and APRI studies (p<0.001). 
This may raise doubts regarding the validity of pooling data from studies evaluating the latter 
two tests, hence these results should be interpreted with caution. Operator bias and 
inter/intra-observer agreement on the diagnosis of OV are also important factors to consider, 
hence our primary outcome was presence of any OV (present vs. absent) rather than 
medium/large OV in order to minimize bias introduced by variability in classification systems 
used across different studies to define the size of OV.  
Implications for clinical practice and areas for future research 
Findings from this study have several important implications for clinical practice. We 
identified the currently available non-invasive markers for the detection of OV and obtained 
global estimates of their accuracy. Pooled data from this systematic review should be used 
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in health economic modelling studies to evaluate the cost-effectiveness of different markers 
in screening for OV.  
PSR was found to be the most accurate marker and its potential is enhanced by the fact that 
its components are readily available in clinical practice as part of standard care (i.e. platelet 
count and ultrasound). A criticism of PSR is the subjectivity in measurement of spleen 
bipolar diameter, but studies have shown the latter to be a reliable parameter with excellent 
reproducibility as measured by both kappa statistic and intra-class correlation coefficient 42, 
43.  
LSM by transient elastography, was the second most accurate diagnostic test in this study, 
and has validated diagnostic accuracy for the detection of cirrhosis across mixed aetiologies 
44. The advantage is therefore one test could be used to diagnose cirrhosis and also stratify 
for OV; however, the precise thresholds for diagnosing OV are yet to be defined 8, 44. As 
highlighted by this systematic review, the range of thresholds ranged from 13.9 kPa to 21.5 
kPa. Transient elastography requires trained operators and has a small but significant failure 
rate in 3-5% of patients 45, 46. Stiffness-based methods have a various proportion of non-valid 
results, and therefore the actual outcome of the studies that use these methods should 
incorporate non-valid measurements among the failures of the test. 
We demonstrate that adopting PSR at the 909 cut-off into clinical practice can result in a 
significant (≥55%) saving of unnecessary OGDs in populations with ≤30% prevalence for 
OV. This will reduce the cost of screening and focus efforts on the remaining patients who 
require an OGD (PSR test positive) by, for instance, allocating them to more specialist lists 
operated by endoscopists with expertise in diagnosis and management. The major clinical 
consequence of misdiagnosis is to fail to detect OV which could bleed in the future. The 
false negative percentage in compensated cirrhosis was in the range of 1-6% (Figure 4), and 
it is important to note that not all of these would require prophylaxis with either band ligation 
or pharmacological therapy in the context of early compensated cirrhosis (i.e. primary 
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prophylaxis is currently recommended for medium/large OV in this cohort) 1.  In contrast, the 
percentage of false negative tests will rise in decompensated cirrhosis (as illustrated by the 
relationship between the incorrectly saved OGDs and prevalence of OV in Figure 4) and the 
consequences of missing OV will be more significant as mortality and morbidity are higher in 
this cohort 9. This gives further credence to the concept of stratifying compensated versus 
decompensated cirrhosis before applying a diagnostic test for OV.  
Conclusions 
Several non-invasive markers have been evaluated to screen for OV in patients with 
compensated cirrhosis. PSR appears to be the most accurate in detecting any size OV 
compared to other tests. It is also the most frequently studied test with promising clinical 
applicability. Based on current estimates, initial screening with PSR at a cut-off of 909, can 
result in correctly saving unnecessary endoscopies in a significant proportion of patients. 
This benefit is highest and the risk of missing OV is lowest with lower prevalence rates for 
the target condition in the tested population. Prospective validation studies, including 
randomized controlled trials, are needed to confirm these findings and assess the impact of 
these diagnostic interventions on robust end-points such as the number of variceal bleeds or 
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Figure 1. Flow diagram of the search strategy and selection of studies eligible for data 
analysis. OGD, oesophagogastroduodenoscopy. 
Figure 2. Forest plots of studies evaluating the sensitivity (top) and specificity (bottom) of 
platelet count/spleen diameter ratio for the diagnosis of any size oesophageal varices in 
patients with compensated cirrhosis. *studies using 909 cut-off. 
Figure 3. Forest plots of studies evaluating the sensitivity (top) and specificity (bottom) of 
liver stiffness measurement by transient elastography for the diagnosis of any size 
oesophageal varices in patients with compensated cirrhosis. 
Figure 4. Bar chart representation of the proportion of endoscopies saved in a cohort of 
patients with compensated cirrhosis undergoing pre-screening test with PSR at a cut-off of 
909. TP, true positive; FP, false positive; FN, false negative; TN, true negative.  
*Example calculation: at a prevalence of 30% for OV = 30% with “disease” and 70% with “no disease”, therefore 
TP = sensitivity (0.87) * prevalence (30%) = 26% and the remaining 4% are FN. Similarly, TN = specificity (0.78) 
* 1-prevalence (70%) = 55% and the remaining 15% are FP. Hence correctly saved = TN = 55%; incorrectly 
saved = FN = 4%; and performed = TP + FP = 26% + 15% = 41%. Based on Fagan’s nomogram (top image), the 
post-test probability of a negative test is 6.4% (6.4% of those who test negative (TN+FN) will have the disease 
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PSR Any OV 792 83, 60 
HOMA-IR score Any OV 3.5 61, 76 




















PSR Any OV 1574 100, 85 
Platelet count Any OV 221*103/microL 86, 54 








PSR Any OV 1883 98, 26 
LSM (Fibroscan) Any OV 16.4 kPa 96, 60 
SSM (Fibroscan) Any OV 41.3 kPa 98, 66 















Any OV 800 74, 70 
Med+ OV 640 73, 65 
LSM (Fibroscan) 
Any OV 17 kPa 71, 57 
Med+ OV 19 kPa 72, 55 
Modified SSM 
b 
Any OV 50 kPa 65, 61 
Med+ OV 54 kPa 80, 70 
AST:ALT ratio 
Any OV 0.8 69, 67 
Med+ OV 1 69, 72 
APRI 
Any OV 1.5 67, 52 
Med+ OV 2 60, 56 
Page 20 of 38
htpp://mc.manuscriptcentral.com/UEGH





































































Any OV 12 kPa 67, 77 
Med+ OV 
c 
21 kPa 77, 87 
Platelet count 
Any OV 117*103/microL 67, 73 
Med+ OV 110*103/microL 85, 72 
APRI 
Any OV 0.77 71, 67 






165 LSM (Fibroscan) 
Any OV 13.9 kPa 95, 43 








Any OV 21.5 kPa 76, 78 
Med+ OV 30.5 kPa 77, 85 
Fibrotest 
Any OV 0.78 72, 69 
Med+ OV 0.78 77, 61 
Prothrombin index 
Any OV 80% 44, 84 
Med+ OV 80% 62, 82 
AST:ALT ratio 
Any OV 1 68, 89 
Med+ OV 1 69, 77 
Lok Index 
Any OV 0.6 68, 82 
Med+ OV 0.6 85, 75 
Platelet count 
Any OV 140*103/microL 56, 76 
Med+ OV 140*103/microL 77, 75 
APRI 
Any OV 1.3 68, 64 







LSM (Fibroscan) Med+ OV 19.8 kPa 91, 56 






74 Platelet count Med+ OV 
d 






70 Regression Model 
Any OV 7 80, 100 









Any OV 0.7 58, 85 
U/S Doppler 
f 
Any OV 0.07 79, 23 
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LSPS Any OV 3.21 81, 86 



























226 SSM (ARFI) 
Any OV 3.18 m/s 98, 63 
Med+ OV 
c 







Any OV <10% 98, 52 
Any OV ≥22.9% 54, 90 
Med+ OV <13.3% 100, 42 
Med+ OV ≥22.9%  58, 73 
No. of pts, number of patients included in the 2X2 table; OV, oesophageal varices; Se, sensitivity (%); Sp, 
specificity (%); Med+, medium/large as defined by classification system used in each study; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase; PSR, platelet count/spleen diameter ratio; SSM, spleen 
stiffness measurement; LSM, liver stiffness measurement; ARFI, acoustic radiation force impulse; U/S, 
ultrasound; ICG-r15, indocyanine green 15-minute retention.
 a 
Italy, Austria, and USA. 
b
 Fibroscan using a 
modified software version with a range between 1.5 and 150 kPa. 
g
 training cohort, data for validation cohort not 
extractable. 
h
 Training cohort. 
i
 Validation cohort. 
j
 All cohort. 
c
 included grade I with high-risk stigmata for 
bleeding or any grade II or III OV. 
d





 Portal Congestive Index. 
k
 Spleno-portal index. HOMA-IR, homeostasis model assessment-
Insulin resistance = fasting insulin (µU/mL) x fasting glucose (mmol/L) / 22.5); LSPS ratio, liver stiffness 
measurement x spleen diameter/ platelet count; APRI, AST to platelet ratio index = (AST / upper limit of normal) / 
platelets x 100; Fibrotest, = 4.467 x log [α2-macroglobulin (g/L)] - 1.357 x log [haptoglobin (g/L)] + 1.017 x log [γ-
glutamyl transpeptidase (IU/L)] + 0.0281 x [age (in years)] + 1.737 x log [bilirubin (µmol/L)] - 1.184 x 
[apolipoprotein A1 (g/L)] + 0.301 x sex (female = 0, male = 1) − 5.540; Prothrombin index, = (Prothrombin Time 
Control Plasma/ Prothrombin Time Patient Plasma) x 100. Lok index, log odds = -5.56 - 0.0089 x platelets 
(10³/mm³) + 1.26 x (AST/ALT) + 5.27 x INR. OV risk score, = - 4.364 + 0.538 x spleen diameter – 0.049 x 
platelet count – 0.044 x LS + 0.001 x (LS x platelet count). 
 
Page 22 of 38
htpp://mc.manuscriptcentral.com/UEGH






























































Table 2. Baseline characteristics of patients included in the systematic review and meta-
analysis. 
Study author/year Country 
Mean 
age, y 










n/s n/s n/s 34 
Camma
22
 2009 Italy 61.4 57.7 100 (HCV) 61 (10) 
Agha
23





Egypt n/s n/s 100 (HCV) 30 
Esmat
25
 2011 Egypt n/s n/s 100 (HCV) 45 
Colecchia
26
 2012 Italy 54 71 100 (HCV) 53 (26) 
Mangone
27
 2012 Italy 62.8 58.6 
63 (HCV), 11 (HBV),  






 2013 Italy 63.2 69.8 100 (HCV) 56 (27) 
Wang
29
 2012 Taiwan 54.5 73.8 100 (HBV) 38 (10) 
Kazemi
30
 2006 France 56 67 
59 (HCV), 10 (HBV),  




 2009 France 54.1 60 100 (HCV) 36 (19) 
Pritchett
32
 2011 Canada 53.3 72 
73 (HCV), 9 (HBV),  




 2007 USA n/s n/s n/s 56 (9) 
Emam
34
 2009 Egypt 43.5 55.7 n/s 64 (29) 
Colli
35
 2001 Italy 49.8 76 
45 (HCV), 36 (alcohol), 




 2008 Italy 60.1 58.3 





 2013 Italy/Spain 60 70.1 
67 (HCV), 9 (HBV),  








55 (HCV), 28 (HBV),  





50 (HCV), 36 (HBV), 




 2013 Japan n/s n/s n/s 27 
Lisotti
40
 2014  Italy 60.3 69.7 
59 (HCV), 14 (HBV),  
20 (alcohol), 7 (other) 
48 (13) 
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%, percentage; OV, oesophageal varices; med+, medium/large; n/s, not stated; HCV, hepatitis C virus; HBV, 
hepatitis B virus. 
a
 Italy, Austria, and USA. 
c
 Training cohort. 
d
 Validation cohort.  
b 
Other includes non-alcoholic 
fatty liver disease, mixed viral and alcohol, cryptogenic, hereditary hemochromatosis.   
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Table 3. Random effects meta-analysis results of studies reporting the diagnostic accuracy 
of currently available markers for the detection of oesophageal varices in patients with 
compensated cirrhosis. 



















































































































Data presented as values (95% confidence interval). I
2
 presented as percentage. N, number of studies; Se, 
sensitivity; Sp, specificity; LR+, positive likelihood ratio; LR-, negative likelihood ratio; AUC, area under the curve; 
PSR, platelet count/spleen diameter ratio; LSM, liver stiffness measurement; SSM, spleen stiffness 
measurement; APRI, aspartate aminotransferase (AST) to platelet ratio index; OV, oesophageal varices; med+, 
medium/large. 
a
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Supplementary Table 1. Search strategy: 
The literature search was performed independently by 2 investigators (SSS and DH), who 
screened titles and abstracts of all articles identified and excluded those with no relevance to 
the research question. The full text of all remaining articles was read in full to ensure that 
they met the inclusion criteria.  
Component Number Defined Search 
Target 
Condition 
#1 exp "Esophageal and Gastric Varices"/ 
#2 (Esophag* varic* or esophag* varix or oesophag* varic* or oesophagi* 
varix or gastroesophag* varic* or gastroesophag* varix or 
gastrooesophag* varic*or gastrooesophag* varix or gastric varic* or 
gastric varix) 
#3 (hvpg or hepatic venous pressure gradient or hepat* vein* or hepat* ven*) 
#4 1 or 2 or 3 
Index Tests #5 (AST:ALT ratio or aspartate aminotransferase or alanine 
aminotransferase or apri or BARD scor* or ELF test* or ELF scor* or 
enhanced liver fibrosis panel* or fib4 or fib 4 or fibroindex or fibrometer or 
fibrotest or forns or hepascore or lok index* or lok scor* or nafld fibrosis 
scor*  or platelet* or thrombocyto* or pohl index* or pohl scor* or testa 
scor* or testa index*) 
#6 (capsule endoscop* or endoscop* capsule or capsule enteroscop* or 
enteroscop* capsule or pillcam or ct scan* or cat scan* or helical ct* or 
mri or magnetic resonance imag* or mr angiogra* or magnetic resonance 
angiogra* or mr elastogra* or magnetic resonance elastogra* or nmr 
imag* or sple* imag* or sple* enlarg* or sple* stiff* or sple* length* 
platelet sple* ratio or platelet sple* index or transient elastogr* or 
fibroscan or liver stiff* or ultraso* or arfi imag*) 
#7 exp Angiogenic Proteins/ 
#8 exp Biological Markers/ 
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#9 exp Diagnostic Imaging/ 
#10 5 or 6 or 7 or 8 or 9 
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 2003 Unclear High Unclear High Low Low Low 
Giannini
26
 2006 High Low Low Low Low Low Low 
Camma
27
 2009 Low High Low Low Low Low Low 
Agha
28





Low High Low Unclear Low Low Low 
Esmat
30
 2011 Unclear High High Unclear Low Low Low 
Colecchia
31
 2012 Low High Unclear High Low Low Low 
Mangone
32
 2012 Low Low Low Low Low Low Low 
Calvaruso
33
 2013 Low Unclear Unclear Low Low Low Low 
Wang
34
 2012 Low Low Unclear Unclear Unclear Low Low 
Kazemi
35
 2006 Unclear High Low High Low Low Low 
Castera
36
 2009 Low High High High Low Low Low 
Pritchett
37
 2011 High High Unclear High Unclear Unclear High 
Burton Jr
38
 2007 Low High High Unclear Low Low Low 
Emam
39
 2009 Unclear High Unclear High Low Low Low 
Colli
40
 2001 Low Low Low Low Low Low Low 
Berzigotti
41
 2008 Low High Unclear Unclear Low Low Low 
Berzigotti
42
 2013 Low Unclear Unclear High Low Low Low 
Liu
43
 2008 High Unclear Low Low Low Low Low 
Takuma
44
 2013 Low Low Low Low Low Low Low 
Lisotti
45
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Supplementary Table 3. Subgroup analysis of studies reporting the diagnostic test 
performance characteristics of platelet count/spleen diameter ratio for the detection of 
oesophageal varices in patients with compensated cirrhosis. 






















































































































































Data presented as values (95% confidence interval). . I
2
 presented as percentage. *The pooled prevalence of 
varices across the eight studies was 0.43. N, number of studies; LR+, positive likelihood ratio; LR-, negative 
likelihood ratio; DOR, diagnostic odds ratio; prosp, prospective; retro, retrospective. 
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Supplementary Figure 1. Summary receiver op rating characteristic (SROC) curve for the 
eight studies evaluating the diagnostic accuracy of platelet count/spleen diameter ratio for 
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Supplementary Figure 2. Summary receiver op rating characteristic (SROC) curve for the 
four studies evaluating the diagnostic accuracy of liver stiffness measurement by transient 
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Supplementary Figure 3. Fagan’s nomogram calculating the post-test probability of 
oesophageal varices (OV), based on the pre-test probability (prevalence) using platelet 
count/spleen diameter ratio (PSR) at a cut-off of 909. (A) At a hypothetically low pre-test 
probability of 10%, (B) At a pre-test probability of 20% observed in some studies (table 1), 
(C) At a pre-test probability of OV of 30% observed in most studies (table 1), (D) At a pre-
test probability of OV of 40% (pooled prevalence of OV in the 9 studies included), (E) At a 
high pre-test probability of 50% observed in some studies (table 1).  
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